A concentrated extract of Zingiber officinale Roscoe rhizome is supplied as Ginger Liquid Extract Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. The representative procurement code GLE-VG-25 denotes a specification set in which the sum of 6-gingerol, 8-gingerol, and 10-gingerol by HPLC is not less than 25.0% w/w on a dry basis, with 6-gingerol not less than 5.0% w/w. The material is a starting material for further manufacture into licensed or compounded veterinary preparations; it is not a final veterinary medicinal product. It is supplied in 25 kg high-density polyethylene drums with nitrogen headspace, and a solvent-resistant liner is specified because the extract may contain ethanol, propylene glycol, or glycerin/ethanol mixtures depending on the manufacturing route.

A representative compliance matrix for this grade appears below. The values follow general pharmacopoeial methods and current ICH/VICH control strategies for botanical intermediates; lot-specific values are controlled by the certificate of analysis.

Specified organisms are controlled at absence of Salmonella in 10 g and Escherichia coli in 1 g under Ph. Eur. 2.6.13 / USP <62>. These limits are appropriate for oral veterinary products and are tightened when the extract enters parenteral manufacturing.

What Distinguishes Veterinary-Grade Ginger Liquid Extract from Food-Grade Oleoresins and Dry Extracts?

Three operational differences are determinative. The veterinary-grade liquid extract is standardized by HPLC against total gingerol markers rather than by organoleptic pungency or volatile oil content. Its residual solvent profile is controlled under VICH GL18 with class-specific limits: ethanol ≤ 5000 ppm, methanol ≤ 3000 ppm, and hexane ≤ 290 ppm where hexane has been used in extraction. Food-grade oleoresin specifications may address residual solvent only at Codex Alimentarius thresholds or may not report Class 2 solvents. The dry extract powder, by contrast, has reduced residual solvent burden but often shows altered gingerol-to-shogaol ratios because the heat applied during spray drying or vacuum drying converts part of 6-gingerol to 6-shogaol.

A second difference is impurity and documentation depth. Veterinary API supply requires batch-specific certificates of analysis, stability-indicating assay data, and declared elemental impurities under ICH Q3D. This is not always available for food-grade fragrant oil. Third, the liquid extract retains higher apparent viscosity than dry powder and can be metered directly into wet-granulation or liquid-fill operations, but it may phase-separate below 5 °C. That is a logistics and processing property rather than an efficacy claim.

Dispersibility and Granule Load Limits in Tableting and Premix Operations

Dry-form conversion of the liquid extract begins with adsorptive carrier selection. On a twin-screw wet granulator having a length-to-diameter ratio of 20:1, addition through a gear pump at 0.5–2.0 kg/h per 10 kg dry blend produces acceptable granule friability when final granule moisture is held below 3.5% w/w. In rotary tablet compression, capping incidence rises when the extract load exceeds 15% w/w of the final granule and compression force is increased above 18 kN; this is an operational boundary derived from standard tableting practice for botanical extracts, not a universal limit for all formulations.

Capsule filling requires pre-adsorption onto microcrystalline cellulose or colloidal silicon dioxide at extract-to-carrier ratios between 1:1 w/w and 1:2 w/w. Hard gelatin shells may soften if residual ethanol remains above 5000 ppm, whereas hypromellose shells tolerate ethanol better but may show slower dissolution when extract droplets are not fully adsorbed onto a hydrophilic carrier. For powders, granules, and premix, the liquid extract is first dispersed onto precipitated silica at 2–5% w/w of the extract load before addition to a ribbon mixer; direct addition to a ribbon mixer without pre-blend can generate localized oleoresin agglomerates and blend uniformity values above 5% RSD in medicated feed premix.

Granule routes are generally preferred for sachets and feed premix because adsorbed extract reduces dust, but the adsorptive carrier can occupy formulation volume and reduce compactibility. Batch-to-batch variation in extract viscosity, measured between 800 mPa·s and 2500 mPa·s at 25 °C depending on vehicle and lot, may require adjustment of the metering pump. When propylene glycol is the primary vehicle, the extract is more hygroscopic than ethanol-based material; granulation may require pre-dried excipients or a fluid-bed inlet air dew point below 5 °C.

When Injectable Formulations Require Bacterial Endotoxin and Particulate Control

Injectable use imposes additional controls not present in oral-grade material. The liquid extract is not sterile as supplied; it must be dissolved or diluted in a membrane-filterable solvent system and clarified through 0.45 µm followed by 0.22 µm filters before aseptic fill, unless terminal sterilization is validated. Steam sterilization at 121 °C for 15 minutes causes partial conversion of 6-gingerol to 6-shogaol and darkening; published data for this specific extract configuration is limited, and a forced degradation study under VICH stability conditions is required before terminal sterilization is used.

Parenteral-grade lots are controlled for bacterial endotoxin at ≤ 0.50 EU/mL by Ph. Eur. 2.6.14 / USP <85>. In process, the final solution should meet particulate limits under USP <788>; subvisible particle counts above 10 particles per mL at the 10 µm threshold require additional filtration or a different solvent system. Solubilization commonly uses propylene glycol, PEG 300, or glycofurol at 30–50% v/v. Aqueous dilution below 30% v/v co-solvent can cause precipitation of ginger resin, particularly at storage temperatures below 10 °C; pH adjustment to 4.0–5.0 and the addition of polysorbate 80 at 0.1–0.3% w/w may reduce this risk, but phase stability must be verified by dynamic light scattering or turbidimetry.

Bacterial and fungal bioburden limits for parenteral-grade liquid extract are tighter than for oral premix: total aerobic microbial count ≤ 10² CFU/g, total yeast and mould count ≤ 10 CFU/g, and Staphylococcus aureus absent in 1 g. The extract should not be introduced into an aseptic filling line without prior bioburden reduction because the natural load can challenge sterilizing filters if filter area is insufficient; a prefilter of 0.45 µm is required upstream of the 0.22 µm sterilizing membrane.

Addition to oral solutions and drenches in multi-dose livestock pumps requires a filterable dispersion with a cloud point above 5 °C to prevent nozzle obstruction. A typical oral drench carrier uses 5–10% w/w liquid extract, 20–30% w/w propylene glycol, 0.1–0.2% w/w polysorbate 80, and buffered water to pH 4.0–5.0. If the pH drops below 3.2, acid-catalyzed dehydration of 6-gingerol to 6-shogaol accelerates; this increases pungency and changes the marker profile, so acid buffers should be validated by HPLC stability data. Solutions for drinking water use a concentrated pre-solution diluted at the farm; the pre-solution must remain free of sediment after 72 h at 25 °C and after 5 °C cold storage, with visible precipitation assessed by microscopy rather than visual inspection alone.

In oral liquid forms, the extract’s inherent viscosity and resinous character can produce surface adherence to stainless steel transfer piping. Clean-in-place systems using 0.1 M sodium hydroxide at 60–70 °C followed by potable water rinse remove residual ginger resin more effectively than cold water alone. This is a plant-cleaning requirement rather than a product specification; it affects batch changeover time when the same line is used for antibiotic premixes or probiotics.

Between-lot marker variability in Zingiber officinale rhizome is controlled by blending extraction batches to a total gingerol assay window of 25.0–27.0% w/w. HPLC integration uses a diode array detector at 280 nm with a C18 column, where 6-gingerol elutes before 8-gingerol and 10-gingerol; any lot with a 6-shogaol-to-6-gingerol area ratio above 0.10 is flagged for degradation or excessive thermal exposure. This is a control point not required for food-grade oleoresin.

The liquid extract is filled under nitrogen into HDPE drums lined with a solvent-resistant barrier. Storage at 15–25 °C in closed containers is recommended; excursions above 40 °C for more than 48 h may increase the shogaol ratio and reduce the required total gingerol content. A slight sediment may appear in drums stored below 5 °C; homogenization at 25 °C for 2 h before sampling is required, and the sample is representative only if the specific gravity after mixing falls within the specified range.

Solubility Limits, pH Boundaries, and Oxidative Degradation Pathways

The extract is freely miscible with ethanol, isopropanol, benzyl alcohol, and propylene glycol; in water it forms turbid dispersions at dilution ratios above 1:10 v/v without emulsifier. Alkalization above pH 7.5 causes darkening and loss of gingerol marker content; oxidation is retarded by ascorbyl palmitate at 0.1% w/w or nitrogen blanketing, but sulfite antioxidants should be avoided because they can react with gingerols and alter the HPLC profile. Combination with strong mineral acids, oxidizing agents, or high-concentration cationic surfactants may cause precipitation or phase inversion. Short-term heating to 60 °C for batch transfer should not exceed 4 h unless forced degradation data support a longer hold. For tablets and capsules, the extract is incompatible with strongly alkaline direct-compression fillers, such as some grades of dibasic calcium phosphate dihydrate above pH 7.0, unless the extract is pre-neutralized or encapsulated in a protective granule.

Aqueous granulation of the extract with povidone or copovidone is possible only when the residual ethanol level is below 1000 ppm because higher ethanol can plasticize the binder and produce sticking during compression. The pH of the granulating fluid should be measured, not assumed, and adjusted to 4.5–5.5 before spraying. These are compatibility boundaries, not efficacy statements.